Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2017-09-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
内部审计工作实施办法（2017年9月）
Regulatory Filings Classification · 95% confidence The document is titled '内部审计工作实施办法' which translates to 'Internal Audit Work Implementation Measures' and details the internal audit policies, procedures, responsibilities, and reporting within the company. It is a comprehensive internal audit manual or guideline document, not an audit report itself. It does not contain financial statements, audit opinions, or results of an audit engagement. It is a regulatory or procedural document outlining internal audit functions and governance. Therefore, it does not fit the category of an Audit Report (AR) which requires standalone audit reports or results. It is also not an Annual Report, Interim Report, or any financial disclosure. The document is a regulatory or compliance-related internal governance document. Given the definitions, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not neatly fit into other categories, especially internal governance or procedural documents.
2017-09-25 Chinese
独立董事工作制度（2017年9月）
Governance Information Classification · 95% confidence The document is titled '厦门艾德生物医药科技股份有限公司 独立董事工作制度' which translates to 'Xiamen Aide Biomedical Technology Co., Ltd. Independent Director Work System'. It details the rules, conditions, nomination, rights, obligations, and protections related to independent directors of the company. The content focuses on governance structure, director qualifications, election procedures, duties, and related governance policies. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document outlining internal rules and practices for independent directors, which fits the definition of Governance Information (CGR).
2017-09-25 Chinese
董事会薪酬与考核委员会议事规则（2017年9月）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Rules" of Xiamen Aide Biomedical Technology Co., Ltd. It details the composition, responsibilities, meeting procedures, voting rules, and confidentiality obligations of the remuneration and assessment committee under the board of directors. The content is focused on governance practices related to board committees and executive compensation management. There is no financial data, earnings information, or regulatory filing announcements. It is not a report of financial results or an announcement of voting results. The document is a governance-related internal rules document describing the structure and operation of a board committee. Therefore, it fits best under Governance Information (CGR). The document length (7279 characters) and detailed procedural content support this classification with high confidence.
2017-09-25 Chinese
董事会战略发展委员会议事规则（2017年9月）
Governance Information Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司 董事会战略发展委员会议事规则," which translates to "Xiamen Aide Biomedical Technology Co., Ltd. Board Strategic Development Committee Rules of Procedure." The content details the rules, composition, responsibilities, meeting procedures, and record-keeping of a board committee focused on strategic development. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is a governance-related internal rules document for a board committee. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and contains detailed governance rules, not just an announcement or summary, so it is not RPA or RNS.
2017-09-25 Chinese
监事会议事规则（2017年9月）
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' for Xiamen Aide Biomedical Technology Co., Ltd. It details the procedures, rules, and governance structure for the supervisory board meetings, including meeting frequency, proposal submission, voting procedures, record keeping, and confidentiality. There is no financial data, no report of financial results, no announcement of voting results, no executive changes, no legal proceedings, no capital updates, and no earnings information. The document is a governance-related internal rules document focused on the supervisory board's operation and meeting procedures. Therefore, it fits best under Governance Information (CGR). The document length is 3539 characters, which is sufficient for a detailed governance document but not a short announcement. Hence, the classification is CGR with high confidence.
2017-09-25 Chinese
董事会议事规则（2017年9月）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors Meetings" of Xiamen Aide Biomedical Technology Co., Ltd. The content details the procedures, responsibilities, meeting types, voting rules, and other governance-related aspects of the board meetings. There is no financial data, earnings information, or audit content. It is a governance document outlining internal rules and board structure. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and it is not an announcement or a brief notice, but a full set of governance rules.
2017-09-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.